drugset
drugset / Trial / NCT00284752

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

NCT00284752 ↗

Phase 2 Completed 56 enrolled Kaiser Permanente Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response

Timeline

Start
2005-08
Primary completion
2007-10
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous

Indications

prostate cancer